Stay updated on Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.5.3 to v3.5.4, signaling a new version of the page. This appears to be a minor administrative update rather than a change to the study details or outcomes.
    Difference
    0.1%
    Check dated 2026-05-15T06:53:14.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    The page reflects a minor update to the platform/UI release revision, moving from “Revision: v3.5.2” to “Revision: v3.5.3.” This represents a technical/version change rather than a change to the displayed study information.
    Difference
    0.0%
    Check dated 2026-04-24T06:32:47.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Revision updated to v3.5.2 and the v3.5.0 revision was removed.
    Difference
    0.0%
    Check dated 2026-04-17T02:47:33.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Revision: v3.5.0 added; Revision: v3.4.3 removed, indicating an update to the page’s revision history.
    Difference
    0.0%
    Check dated 2026-03-19T06:24:06.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. The new version is now displayed.
    Difference
    0.0%
    Check dated 2026-03-12T02:16:06.000Z thumbnail image
  9. Check
    113 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 and removed the funding-related notice (Revision: v3.4.1); these changes do not modify the study details, eligibility criteria, or outcomes presented on the page.
    Difference
    0.4%
    Check dated 2026-02-11T14:15:47.000Z thumbnail image

Stay in the know with updates to Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab +/- SD-101 in Oligometastatic Prostate Cancer Clinical Trial page.